吡柔比星与羟基喜树碱预防浅表性膀胱癌术后复发临床分析  

THPand hydroxycamptothecin for prevention of postoperative superficial bladder cancer recurrence clinical analysis

作　　者：李亚县[1] 张凯忠[1] 唐志忠[1] 吴爱明[1] 池月英[1] 黎志钦[1] 周立[1] 曾嘉庆[1] 

机构地区：[1]广东省茂名市人民医院泌尿外科,广东茂名525000

出　　处：《吉林医学》2013年第24期4873-4874,共2页Jilin Medical Journal

摘　　要：目的:将吡柔比星(THP)与羟基喜树碱(HCPT)分别使用以及联合使用(COMB)进行膀胱灌注治疗膀胱癌,对其作用进行评价。方法:随机选择138例浅表性膀胱癌术后患者,平均分为THP、HCPT及COMB共三个小组。采用截然不同的用药方法,分别认真观察各组案例复发率和不良反应等情况进行综合比较。结果:对各组患者均进行24个月随访,患者平均复发率分别为:THP组13.04%,HCPT组19.57%,COMB组6.52%且无不良反应。试验结果表明,COMB组术后复发率及不良反应率均明显低于单独用药的THP组和HCPT组。结论:吡柔比星和羟基喜树碱两种药物联合使用,对于膀胱癌的手术复发治疗预防效果明显,值得加强推广使用。Objective The clinical treatment of bladder cancer,will of pirarubicin（THP） with Hydroxycamptothecin（HCPT） were used as well as the combined use of COMB for bladder perfusion,its effect evaluation.Methods Randomly choose 138 cases of postoperative superficial bladder cancer patients,divided into THP,HCPT and COMB in all three groups.Using different treatment methods,were carefully observed case recurrence rate and adverse reaction and so on comprehensive comparison.Results All patients were followed up for 24 months,with an average recurrence rates were：13.04% in group THP,group HCPT 19.57%,COMB 6.52% and no adverse reaction.The test results show that,the COMB group of recurrence rates and adverse reaction rates were lower than medication alone in THP group and HCPT group.Conclusion THP HCPT and a combination of two drugs for bladder cancer,the operation treatment for recurrence prevention effect,is worth promoting the used.

关 键 词：膀胱癌 羟基喜树碱 吡柔比星 膀胱灌注 复发 

分 类 号：R737.14[医药卫生—肿瘤]